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Abstract: In this work, a novel membrane crystallization system was used to crystallize micro-sized
seeds of piroxicam monohydrate by reverse antisolvent addition. Membrane crystallization seeds
were compared with seeds produced by conventional antisolvent addition and polymorphic
transformation of a fine powdered sample of piroxicam form I in water. The membrane crystallization
process allowed for a consistent production of pure monohydrate crystals with narrow size
distribution and without significant agglomeration. The seeds were grown in 350 g of 20:80
w/w acetone-water mixture. Different seeding loads were tested and temperature cycling was
applied in order to avoid agglomeration of the growing crystals during the process. Focused beam
reflectance measurement (FBRM); and particle vision and measurement (PVM) were used to monitor
crystal growth; nucleation and agglomeration during the seeded experiments. Furthermore; Raman
spectroscopy was used to monitor solute concentration and estimate the overall yield of the process.
Membrane crystallization was proved to be the most convenient and consistent method to produce
seeds of highly agglomerating compounds; which can be grown via cooling crystallization and
temperature cycling.
Keywords: agglomeration; membrane crystallization; temperature cycling; seeded crystallization
1. Introduction
Crystal agglomeration is a common phenomenon for many chemical and pharmaceutical
compounds. It is usually undesirable since the formation of agglomerates promotes the entrapment
of mother liquid and, therefore, compromises the purity of the dried product. Furthermore, particle
agglomeration can generate broad crystal size distributions (CSD) and induce the formation of a large
amount of fines during storage and transport [1,2].
The effect of operating parameters on crystal agglomeration during crystallization processes
has been studied via both experimental and modelling work [2,3]. The main variables affecting
agglomeration were found to be solid content in suspension, particle size, stirring rate, and
supersaturation at seeding or nucleation. Furthermore, both solvent and solute physical and chemical
characteristics were found to strongly affect this phenomenon [1,4,5]. Recently, the effect of particle
morphology on crystal agglomeration was studied using a novel image analysis routine [6]. An
opportune choice of solvent, careful seeding and temperature cycling can largely decrease the
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degree of agglomeration. In fact, repeated cycles of heating and cooling were found to promote
de-agglomeration [7].
In some cases, the formation of regular agglomerates (mostly spherical) is desired, since they are
easy to handle during downstream operations and can be more efficiently compacted [8]. Spherical
agglomerates can be formed using a bridging liquid [9,10], a specific additive [11] or by cooling an
oil-in-water emulsion where the crystallizing solution is localized within oil droplets [12]. Spherical
agglomerates have recently been produced successfully in a continuous MSMPR (mixed suspension,
mixed product removal) reactor [12] and in a microfluidic device [13].
Large agglomerates of poorly water soluble drugs can also be obtained in the form of crystanules,
particles with mixed characteristics of both crystals and granules. These are produced by melting the
insoluble drug and forming an emulsion consisted of drug droplets in water. The droplets are then
solidified, by cooling, in the form of large agglomerates. The addition of a polymeric additive can
improve the mechanical properties of these crystanules [14–16].
Membrane crystallization is a relatively new technique based on the use of a porous material as a
semi-permeable barrier between two phases. The membrane can be used to create supersaturation by
solvent evaporation, antisolvent or reactant addition, and mixing with a colder solvent [17,18]. The
first membrane crystallization process dates back to 1917 when Kober used a polymeric membrane to
evaporate water from aqueous solutions of ammonium sulfate and hydrochloric acid, and precipitated
salts upon increasing the solution supersaturation [18]. Renewed interest in membrane crystallization
aroused in the 80’s when microporous membranes for water treatment became popular [19]. Membrane
distillation and reverse osmosis processes were proposed and applied [20,21]. More recently,
membranes were used to crystallize proteins and macromolecules [22–24]. The presence of a membrane
adds a supplementary resistance to mass transfer, but it also offers additional control over the
nucleation kinetics (the nature of the membrane can significantly change the surface tension of the
crystallized material) and polymorphic outcome of crystallization [25–27].
In this work, a flat isoporous nickel membrane installed in a stirred cell was used to produce
micro-seeds of piroxicam monohydrate by reverse antisolvent addition. Piroxicam is a non-steroidal
anti-inflammatory drug; it can crystallize in two different polymorphs or as monohydrate in the
presence of water. This last form is characterized by high tendency of agglomeration. The membrane
crystallization procedure used in this work allows producing non-agglomerated crystals of piroxicam
monohydrate with narrow CSD, which can easily be filtered and dried [28,29], or used as seeds while
still in slurry. The use of the membrane guarantees a higher polymorphic purity, lower tendency to
agglomeration, and a narrower crystal size distribution compared to traditional batch crystallization
techniques (cooling, antisolvent or reverse antisolvent addition) [28,29]. Seed crystals produced
by membrane crystallization were compared to those prepared using traditional batch techniques.
Furthermore, a specific cooling profile with temperature cycling was determined and applied in order
to reduce agglomeration and promote crystal growth of the seed crystals. The experimental results
show that a combination of specifically tailored membrane crystallization seeds and temperature
cycling can efficiently reduce agglomeration and promote crystal growth of piroxicam monohydrate.
2. Materials and Methods
Piroxicam (99% purity) was purchased from Hangzhou Hyper Chemicals Limited (Hangzhou,
China). Acetone (99.98% purity) purchased from Fisher Scientific (Loughborough, UK) and de-ionized
water (Millipore ultra-pure system) were used as solvent and antisolvent for the drug. A 400 mL
jacketed glass vessel was used to carry out the 350 g cooling crystallization experiments. The vessel
was equipped with an overhead polytetrafluoroethylene (PTFE) pitch blade stirrer (325 rpm was the
stirring speed used in all experiments). A schematic of the rig used for the experiments is shown in
Figure 1.
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partly, by agglomeration. After the isothermal period, in order to remove the fine crystals generated by
secondary nucleation and reduce agglomeration, temperature cycling was applied.
Slurries underwent nine temperature cycles of 20 ◦C amplitude with heating/cooling rate of
±0.2 ◦C/min. The cycles’ amplitude and rates were chosen, based on preliminary experiments
(see Supplementary Materials Figures S1 and S2), in order to accelerate the dissolution of fines and
de-agglomeration [29].
In addition to the use of fixed amplitude cycles, direct nucleation control (DNC) was also tested.
The details of this control strategy are described elsewhere [7,32–35]. Experimental results for the two
DNC experiments performed are shown in the Supplementary Materials Figures S8–S11).
2.2. Seeds Preparation
Seed crystals were prepared using membrane crystallization, antisolvent crystallization, and
polymorphic transformation, as described in the following sections. Cooling crystallization with in
situ nucleation was also performed but seed crystals could not be produced in a reasonable batch time
because of the very slow kinetics of primary nucleation for piroxicam monohydrate.
2.2.1. Membrane Crystallization
Piroxicam microcrystals were prepared by reverse antisolvent addition using a flat, disc-shaped
membrane installed in a stirred cell, as shown in Figure 2a. The cell and membranes were purchased
from Micropore Technologies Ltd. (Derby, UK). This apparatus is normally used for membrane
emulsification, a gentle process for the formation of droplets and particles in the micron range [36–38].
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Figure 2. (a) Schematic of the rig used for membrane crystallization; (b) Scanning electron microscope
(SEM) image of the Ni membrane used for the experiments.
The rotation speed of the stirrer was fixed to 1500 rpm, corresponding to a peak shear stress
at the membrane surface of 17.5 Pa. A 24 V direct current (DC) motor (Instek model PR-3060, New
Taipei City, Taiwan) was used to drive the stirrer. The nickel membrane used for the experiments had
an operative area of 8.55 cm2 and an effective diameter of 3.3 cm. It presented ≈24,690 pores with
diameter of 40 µm, arranged hexagonally and spaced apart at a constant distance of 200 µm, as shown
in the scanning electron microscope (SEM, Hitachi Ltd., Tokyo, Japan) image of Figure 2b.
The membrane was placed at the bottom of the cell which was filled with 30 mL of deionized water.
A solution containing 15 g·L−1 of piroxicam in acetone was injected through the membrane using
a syringe pump (Harvard Apparatus model 11 Elite, Harvard Apparatus, Holliston, United States).
The feed flow rate through the membrane was 18 mL·min−1, corresponding to a transmembrane
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flux of 4000 L m−2·h−1). The total volume of the feed solution injected was 6 mL and the volume
mean diameter of microcrystals was between 25–35 µm, as measured by Malvern Mastersizer 2000
(with a Hydro 2000SM dispersant unit, Malvern Instruments Ltd., Malvern, UK) [29]. In this reverse
antisolvent crystallization procedure, the membrane acts as a physical support for the generation
and sustenance of a controlled supersaturation for the nucleation and growth of the crystals. The
feed is injected into the aqueous phase through multiple equally spaced injection microjets where
individual crystals can nucleate and grow before being transferred to the bulk as the result of the
shear stress created by the stirrer. This procedure allows the production of crystals with very narrow
CSD, as well as low agglomeration tendency. Crystals smaller than 25 µm can be obtained with the
same apparatus [28], but the 25–35 µm size range was chosen to minimize particle agglomeration
immediately after seeding. After each experiment, the membrane was sonicated in acetone for 30 min,
washed with deionized water in an ultrasonic bath for 5 min and then stored in acetone. The slurry
containing the monohydrate microcrystals was transferred from the cell to a beaker where crystals
were allowed to settle at the bottom. Crystals were then collected with a pipette and transferred
directly to the vessel for the seeded batch experiments. A small amount of sample was used to measure
the CSD using the Malvern Mastersizer 2000 previously described. A saturated solution of piroxicam
monohydrate in water at room temperature was used as dispersant.
2.2.2. Antisolvent Crystallization
Seed crystals from antisolvent crystallization were produced by pumping water with a peristaltic
pump (Masterflex L/S digital drive, Masterflex Technical Hoses Limited, Oldham, UK) at a rate of
2.5 mL/min into a solution of piroxicam in acetone with concentration of 35 mg/g of solvent. The
solution was prepared by dissolving solid piroxicam at 40 ◦C in the 400 mL jacketed vessel. The rate
of antisolvent was chosen after a few preliminary experiments in order to obtain pure monohydrate
piroxicam at the end of the batch. In fact, nucleation of form II of piroxicam was observed using
both faster and slower cooling rates. During the experiments, FBRM and PVM were used to monitor
nucleation, agglomeration and shape of the particles. The Malvern Mastersizer 2000 previously
described was used to measure the CSD of the crystals obtained at the end of the experiments (after
filtration and drying).
2.2.3. Polymorphic Transformation
Piroxicam form I (fine powder as purchased) was suspended in water and left to transform
to monohydrate. A total amount of 2.2 g of piroxicam was suspended in 500 g of water at 20 ◦C.
Raman spectroscopy (ThermoFisher Scientific, Waltham, MA, USA) was used to monitor, in situ, the
polymorphic transformation of form I into piroxicam monohydrate. After transformation, crystals
were filtered and dried, and their CSD was measured by the Malvern Mastersizer previously described.
2.2.4. Cooling Crystallization
Solutions of piroxicam in a 20:80 w/w water-acetone mixture were prepared in the 400 mL vessel,
as described in the Equipment section.
Solutions containing 6.8, 7, 8.8, 11.4, and 14 mg of piroxicam per 1 g of solvent were heated
up until the drug was completely dissolved and then cooled down to 5 ◦C at a cooling rate of
0.5 ◦C/min. Nucleation of monohydrate crystals was not detected either during the cooling profile
or after leaving the solution at 5 ◦C for few hours, indicating very slow primary nucleation kinetics.
In conclusion, piroxicam monohydrate seeds could not be produced in a reasonable batch time
by cooling crystallization with the equipment available, because of the extremely slow primary
nucleation kinetics.
Pharmaceutics 2018, 10, 17 6 of 15
3. Results and Discussion
3.1. Seeds Characterization and Comparison
Seeds obtained by membrane crystallization are shown in Figure 3. Crystals displayed the
characteristic yellow color of piroxicam monohydrate (polymorphic purity was checked with Raman
microscopy and differential scanning calorimetry) and the shape of a prism with a rhombus base.
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These seeds did not show significant agglomeration and they were characterized by a volume
weighted mean diameter measured using the Mastersizer in a range of 25–35 µm. Figure 4d shows the
seeds obtained by antisolvent crystallization; crystals were highly agglomerated and it was difficult to
identify their shape. Raman microscopy confirmed that crystals were pure piroxicam monohydrate
after filtration and drying. However, Figure 4c shows a PVM image taken after nucleation where
several monohydrate agglomerates were observed together with needle-shaped crystals of piroxicam
form II. Most likely, a mixture of monohydrate and form II was nucleated and then converted to the
stable monohydrate during the batch.
The sudden drop in total counts/measurement recorded by the FBRM (Figure 4a,b) was probably
due to the change in crystal shape associated to the polymorphic transformation (from needle-shaped
form II to cubic piroxicam monohydrate). The formation of monohydrate agglomerates might also
have contributed to the decrease in the total counts/measurement.
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Figure 5. (a) Raman signal during polymorphic transformation from form I piroxicam to mon hydrate;
(b) Microscopic image of the monohydrate crystals obtained at the end of the experiment.
Figure 5a shows the intensity of two different Raman peaks, after second derivative and smoothing
calculation. The peak t 1405–1390 cm−1 was associated wit solid pir xicam mo ohydrate, while the
peak at 1550–1537 m−1 was typical of form I. During the polymorphic transformation, the intensity of
the form I peak decreased, while the peak intensity for the monohydrate increased. The polymorphic
transition was also detectable qualitatively by a change of color of the slurry from white (form I)
to bright yellow (monohydrate). The Malvern Mastersizer was used to determine the crystal size
distribution of the three types of seeds. Seeds produced by membrane crystallization were analyzed in
form of slurry, while seeds from antisolvent addition and polymorphic transformation were filtered
and dried before being dispersed in a saturated aqueous solution of piroxicam monohydrate. Figure 6
shows the CSD of the three types of seeds used for this work. Membrane crystallization generated
narrower CSDs than antisolvent addition.
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of the CSD) and the lower volume weighted mean diameter. Further ore, as sho n in the optical
icrographs e brane seeds are less agglomerated compared to the polymorphic transformation
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Table 1. alvern Mastersizer d ta for th seed used, where d(0.1), d(0.5), and d(0.9) are the
particle diameters at 10%, 50% and 90% of the cumulative distribution, pan w s calculated as
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Seeds Type d(0.1) (µm) d(0.5) (µm) d(0.9) (µm) Span(-) D[4,3] (µm) D[3,2] (µm)
Membrane 19.8 ± 1.23 32.5 ± 1.85 53.1 ± 3.62 1.03 ± . 7 34.8 4.25 30.2 ± 1.73
Transformation 28.8 ± 0.49 50.6 ± 0.8 87.5 ± 1.45 1.16 ± 0.0 2 55.0 0.90 46.0 ± 0.78
Antisolvent 65.6 ± 0.05 121 ± 3.39 220.9 ± 12.85 1.28 ± 0.07 134 ± 5.15 101 ± 2.67
3.2. Seeded Growth Experiments
Similar seeded b tch co ling crystallization experim nts were carried out us the three types
of seed crystal prepared. Solutions satu ate at 40 ◦C were prepared by dissolving solid pir xicam
in th chosen s lv nt at 50 ◦C. Seeds we e added after cooling down 37 ◦C, and then the solutions
were further cooled down to 10 ◦C at a rate of −0.1 ◦C/min. In order to fully deplete supersaturation,
the temperatur was kept constant at 10 ◦C. Raman spectroscopy was used to monitor the evolution of
solute concentration. The peak intensity at 1443–1438 cm−1 (after calculat on of second der vative and
smoothing) was used as an indication of the amount of piroxicam dissolved in solution. An inferenti l
solubility cur was determined by measuring the values f intensity of such Raman peak for several
saturated solutions of piroxicam m nohydrate, a different temperatures. A polynomial function was
used to interp late the data and is shown in Figure 7b. The solution supersaturation was c nsumed by
growth, secondary nucleati n and, partly, by agglomeration in abou 8–10 h, indicating slow kinetics
of growth and nucleation. After that, temperature cyc ing was applied to reduce crystal agglomeration
and d ssolve fine crystals. A total of nine cycles of 20 ◦C amplitude was used.
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Figure 7. (a) Total counts and temperature during the seeded experiments with 2% membrane
crystals; (b) Intensity of the Raman peak corresponding to dissolved piroxicam (solute); (c) Trends
for FBRM (Focused Beam Reflectance Measurement) counts and mean of the square weighted chord
length distribution.
The evolution of the total counts/measurement during the experiment is shown in Figure 7a
while Figure 7c shows the most significant FBRM statistics. It can be noticed that after two cycles a
stable oscillatory trend for the total counts/meas. and mean of the squared weighted chord length
distribution was reached. As shown in Figure 7b, the solute concentration during cycling remained
close to equilibrium conditions, indicating a high yield at the end of the experiment.
The trends of the counts/meas. between 50–150 and 150–300 µm (corresponding to the size of
monohydrate agglomerates) also reached a stable trend after two cycles. Microscopic images of the
crystals from filtered and dried samples (Supplementary Materials Figure S3) also showed a decrease
in the number of agglomerates while cycling.
Figure 8 shows the trends for the total counts/measurement for the other three seeded cooling
and cycling experiments. In all cases, a longer time was needed to reach a stable oscillating trend
in the total counts/measurement compared to the seeded experiments with 2% membrane seeds.
In fact, nine cycles were not enough to reach a stable oscillating trend for the antisolvent addition and
Pharmaceutics 2018, 10, 17 10 of 15
6% membrane seeds, as shown in Figure 8a,b. Figure 8c shows that in the case of the polymorphic
transformation seeds, four temperature cycles were needed to reach a stable trend. The maximum
amount of total counts reached after 10 h at 10 ◦C for this last type of seeds was around 2100 total
counts/measurement, significantly lower than the maximum reached for all the other experiments
(between 5000 and 7000 total counts/measurement).
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Figure 8. (a) Total counts and temperature profile for the seeded experiment with 6% membrane seeds;
(b) 2% antisolvent addition seeds; (c) polymorphic transformation seeds.
In order to better compare the crystals obtained at the end of each cycling experiments, microscopic
images are shown in Figure 9. The narrowest CSDs were obtained with membrane seeds and seeds
from polymorphic transformation, as it can be noted in Figure 9a,b,d. The final degree of agglomeration
at the end of each experiment was very similar, as shown in Figure 9. However, in Figure 9c few large
agglomerates could still be identified in the crystals obtained using antisolvent seeds. Microscopic
images of crystals collected at different times during the seeded crystallization experiments can be
found in the Supplementary Materials Figures S3–S7.
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Figure 9. Microscopic images of crystals grown from: (a) membrane seeds (2% of the total mass
of piroxicam); (b) membrane seeds (6% of the total mass of piroxicam); (c) antisolvent seeds;
(d) transformation seeds.
The CSDs and the main statistics for the crystals obtained at the end of the cycling experiments
are shown in Figure 10 and Table 2. The highest increase in volume weighted mean diameter during
the cycling experiment was observed for the membrane seeds: +243% when 2% seeds were used, and
+205% for 6% seeds.
Table 2. Malvern Mastersizer data for the crystals at the end of the seeded experiments, where d(0.1),
d(0.5), and d(0.9) are the particle diameters at 10%, 50% and 90% of the cumulative distribution, Span
was calculated as [d(0.9) − d(0.1)]/d(0.5), and D[4,3] and D[3,2] are the volume and surface weighted
mean diameters, respectively. The table shows the average values of all the measurement replicates
and corresponding standard deviations.
Sample d(0.1) (µm) d(0. ) (µm) d(0.9) (µm) Span(-) D[4,3] (µm) D[ ,2] (µm)
Membrane 2% 78.7 ± 1.21 115 ± 0.46 166 ± 3.61 0.76 0.04 ( 25 ) 119 ± 0.9 (+243 ) 110 ± 0.33 (+263%)
Membrane 6% 67.7 ± 0.31 101 ± 0.70 152 ± 1 60 .83 0.01 (−19 106 0.74 (+205%) 96.7 ± 0.63 (+220%)
Transformation 104 ±0.45 14 ± 0.62 211 ± 0.86 0.72 ± 0.001 (−38%) 53 0.64 ( 179%) 142 0.60 (+209%)
Antisolvent 70.3 ± 1.07 181 ± 1.59 340 ± 1.97 1.49 ± 0.01 (+16%) 195 ± 1.38 (+46%) 138 ± 1.35 (+36%)
A decrease in the span of the distribution (parameter related to its n rowness) was noticeable
for all seeds apart from the ones obtained by antisolve t addition. In particular, the polymo phic
transformation seeds led to the lowest value of th span and its highest decrease. The final crystal size
distributions for each of the cycling experiments are shown in Figure 10.
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While the membrane seeds and the ones from polymorphic transformation generated narrow and
unimodal distributions, the antisolvent seeds led to a very broad CSD with a high amount of fines.
In conclusion, using membrane seeds and polymorphic transformation seeds allowed for a narrow
CSD with low tendency to agglomeration. The number of temperature cycles needed to reach the
equilibrium size and to remove all agglomerates was around 2 for the membrane seeds (2% of the total
mass of piroxicam in solution at the moment of seeding), and 4 for the polymorphic transformation
seeds. Therefore, a shorter batch time was needed when membrane seeds were used in the correct
amount. Furthermore, in order to produce 2 g of polymorphic transformation seeds, a fine powdered
sample of piroxicam form I needed to be suspended in water for over 40 hours, for complete conversion
to the monohydrate form. On the other hand, producing the same amount of membrane seeds does not
require any previous sample preparation and takes only a few seconds. Additionally, membrane seeds
can be produced in a continuous mode with a similar apparatus [28] making this seed production
method particularly efficient for piroxicam and other highly agglomerating compounds.
4. Conclusions
A novel procedure for seeds production was used in combination with temperature cycling to
grow crystals of a highly agglomeration prone compound (piroxicam monohydrate). The membrane
seeds were compared to seeds obtained by conventional antisolvent addition and polymorphic
transformation. Crystals of monohydrate could not be obtained by cooling crystallization with
in situ primary nucleation.
The membrane seeds allowed a narrow crystal size distribution to be obtained at the end of the
batch without significant agglomeration. The quality of the final crystals in terms of final crystal
size distribution was comparable to the one gained using seeds from a polymorphic transformation.
However, membrane seeds can be produced in a faster and more efficient way compared to the
polymorphic transformation ones.
Furthermore, me brane seeds were used in combination with the direct nucleation control
strategy, which led to large crystals with a narrow crystal size distribution and no visible agglomeration.
In conclusion, this study shows that crystal agglomeration can be prevented efficiently by using
a specific seeds preparation and temperature cycling. Agglomeration is an undesired phenomenon
since it causes the broadening of the crystal size distribution and solvent incorporation. Membrane
crystallization is a fast and efficient way to obtain non-agglomerated crystals with narrow CSD, which
can be used as a final product (after filtration and drying) or as seeds when larger crystals are required.
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As shown by the experimental results, this method is particularly useful for compounds with a slow
nucleation rate that cannot be generated at low supersaturation to avoid agglomeration.
Supplementary Materials: The following are available online at www.mdpi.com/1999-4923/10/1/17/s1,
Figure S1: Temperature profile and total counts evolution during a preliminary cycling experiments performed in
order to establish the best cycles’ amplitude and rate, Figure S2: Microscopic images of crystals during the cycling
experiment of Figure S1, Figure S3: Microscopic images of crystals during the cycling experiment 1 (2% membrane
seeds), Figure S4: Microscopic images of crystals during the cycling experiment 2 (6% membrane seeds), Figure S5:
Microscopic images of crystals during the cycling experiment 3 (antisolvent seeds), Figure S6: Microscopic images
of crystals during the cycling experiment 4 (polymorphic transformation seeds), Figure S7: FBRM statistics during
cycling experiments 1, 3 and 4, Figure S8: Temperature, total counts, Raman intensity and microscopic images of
crystals for the DNC experiment 1, Figure S9: Temperature, total counts, Raman intensity and microscopic images
of crystals for the DNC experiment 2, Figure S10: Microscopic images of crystals during the DNC experiment 1,
Figure S11: Microscopic images of crystals during the DNC experiment 2, Table S1: Malvern Mastersizer data for
the seeds and the crystals at the end of the DNC experiment 2.
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